AstraZeneca's new drug farxiga3 for type 2 diabetes has positive results

, a furtheranalysi
s of data from a new drug, http://(http://http://
) of theof theof theof the t2-type diabetes (T2D)a, announced in theof AstraZeneca http://company, http://that Farxiga was able to develop a heart attackThe relative risk of major adverse cardiovascular events (MACE) was reduced by 16%About Farxiga
Farxiga is an innovative selective type 2 sodium-glucose co-transporter protein (SGLT2) inhibitor whose main function is to reduce the reabsorption of glucose in the kidneys by inhibiting the function of the kidneys, thereby achieving the effect of lowering blood sugar levelsWhat makes this therapy unique is that its sugar-lowering effects do not depend on the function of islet beta cells and are not affected by insulin resistanceFarxiga has been approved by theFDA(http://to improve blood sugar control in patients with type 2 diabetes by using diet and exerciseFurther analysis of data from Phase 3 clinical trials called DECLARE-TIMI 58 showed that Farxiga was able to reduce the risk of MACE by a relative 16% (15.2% vs17.8%) compared to placebo, in patients with type 2 diabetes who had had a myocardial infarctionHR: 0.84, 95% CI: 0.72-0.99)Another scheduled subgroup analysis showed that Farxiga was able to reduce the risk of hospitalization for heart failure in people with type 2 diabetes compared to placeboIn patients with reduced blood score, Farxiga was able to reduce the risk of hospitalization for heart failure by a relative 36 percent, and in patients without HFrEF, Farxiga was able to reduce the risk of hospitalization for heart failure by a relative 24 percent